Table 1.
Baseline characteristics of the study cohort.
| Characteristic | Patients, n = 209 (%) |
|---|---|
| Age, mean ± SD, years | 58 ± 11.3 |
| Age at diagnosis, mean ± SD, years | 47 ± 12.1 |
| Age at treatment, mean ± SD, years | 54 ± 10.9 |
| Sex (male) | 117 (56) |
| Ethnicity | |
| Jewish | 201 (96.2) |
| Bedouin | 8 (3.8) |
| Subgrouping | |
| Israeli-born | 74 (35.4) |
| Immigrant—former Soviet Union | 135 (64.6) |
| Genotype | |
| 1a | 34 (16.3) |
| 1b | 121 (57.9) |
| 2a | 9 (4.3) |
| 3 | 38 (18.2) |
| 4a | 4 (1.9) |
| Patient type | |
| Treatment-naïve | 149 (71.3) |
| Experienced past treatment | 58 (27.8) |
| Viral load (IU/mL) | |
| ≤800,000 | 76 (36.4) |
| >800,000 | 133 (63.6) |
| Method of fibrosis assessment at treatment time | |
| Fibrotest | 165 (78.9) |
| Fibroscan | 21 (10) |
| Fibrosis stage at treatment time | |
| F0–F1 | 53 (25.4) |
| F2 | 56 (26.8) |
| F3 | 38 (18.2) |
| F4 | 62 (29.7) |
| Updated fibrosis stage | |
| F0–F1 | 146 (69.9) |
| F2 | 22 (10.5) |
| F3 | 16 (7.7) |
| F4 | 25 (12) |
| Change in fibrosis score | |
| No change in the fibrosis score | 75 (35.9) |
| Regression of fibrosis | |
| 3 stages | 18 (8.6) |
| 2 stages | 38 (18.2) |
| 1 stage | 63 (30.1) |
| Progression of fibrosis | |
| 1 stage | 12 (5.7) |
| 2 stages | 3 (1.4) |
| Regression in the fibrosis score | |
| From F3/F4 to F2 or less | 58 (27.8) |
| Treatment type | |
| Dasabuvir/ombitasvir or paritaprevir/ritonavir | 19 (9.1) |
| Dasabuvir/ombitasvir or paritaprevir/ritonavir/ribavirin | 13 (6.2) |
| Ledipasvir/sofosbuvir | 28 (13.4) |
| Ledipasvir/sofosbuvir/ribavirin | 4 (1.9) |
| Elbasvir/grazoprevir | 39 (18.7) |
| Daclatasvir/sofosbuvir | 4 (1.9) |
| Daclatasvir/sofosbuvir/ribavirin | 16 (2.9) |
| Sofosbuvir/velpatasvir | 49 (23.4) |
| Pibrentasvir/glecaprevir | 45 (21.5) |
| Sustained virologic response (SVR) | 207 (99) |